GlassScriptPhysician profile
Hillary Borsa
NPI 1316323793
$6,878.06
in general payments reported to CMS, 2019-2025
43 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,169 · 2022: $1,300 · 2023: $800 · 2024: $1,538 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,409.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $794.96 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $693.03 | 2021-2025 | |
| Novo Nordisk INC | $593.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.49 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $392.45 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $331.85 | 2021-2025 | Repatha, Krystexxa, Otezla |
| Sage Therapeutics, LLC | $244.26 | 2024-2025 | Zurzuvae |
| Biohaven Pharmaceutical Holding Company LTD. | $240.44 | 2022 | |
| Sumitomo Pharma America, INC. | $236.26 | 2023-2025 | Gemtesa, Myfembree |
| Intuity Medical INC | $235.27 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $199.09 | 2024-2025 | Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $187.99 | 2024-2025 | Veozah |
| Lilly USA, LLC | $185.08 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $141.32 | 2022-2025 | Spravato |
| Dexcom, INC. | $120.77 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Borsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.